- Home
- RGT vs NVNO Comparison
RGT vs NVNO Comparison
Compare RGT & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGT
- NVNO
- Stock Information
- Founded
- RGT 1986
- NVNO 1987
- Country
- RGT United States
- NVNO United States
- Employees
- RGT N/A
- NVNO N/A
- Industry
- RGT Trusts Except Educational Religious and Charitable
- NVNO Medical/Dental Instruments
- Sector
- RGT Finance
- NVNO Health Care
- Exchange
- RGT Nasdaq
- NVNO Nasdaq
- Market Cap
- RGT N/A
- NVNO 41.0M
- IPO Year
- RGT N/A
- NVNO N/A
- Fundamental
- Price
- RGT $10.61
- NVNO $2.74
- Analyst Decision
- RGT
- NVNO
- Analyst Count
- RGT 0
- NVNO 0
- Target Price
- RGT N/A
- NVNO N/A
- AVG Volume (30 Days)
- RGT 22.4K
- NVNO 90.1K
- Earning Date
- RGT 01-01-0001
- NVNO 05-07-2025
- Dividend Yield
- RGT 1.43%
- NVNO N/A
- EPS Growth
- RGT N/A
- NVNO N/A
- EPS
- RGT 0.92
- NVNO N/A
- Revenue
- RGT N/A
- NVNO N/A
- Revenue This Year
- RGT N/A
- NVNO N/A
- Revenue Next Year
- RGT N/A
- NVNO $409.09
- P/E Ratio
- RGT $11.42
- NVNO N/A
- Revenue Growth
- RGT N/A
- NVNO N/A
- 52 Week Low
- RGT $7.84
- NVNO $2.03
- 52 Week High
- RGT $11.08
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- RGT 57.49
- NVNO 56.49
- Support Level
- RGT $9.98
- NVNO $2.61
- Resistance Level
- RGT $10.48
- NVNO $2.79
- Average True Range (ATR)
- RGT 0.29
- NVNO 0.19
- MACD
- RGT 0.09
- NVNO 0.08
- Stochastic Oscillator
- RGT 99.69
- NVNO 92.78
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.